ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Development of institutional guidelines for menstrual suppression and abnormal uterine bleeding in patients undergoing intensive chemotherapy for hematologic malignancies.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBleeding complications significantly contribute to morbidity and mortality of patients with hematologic malignancies. Although there is some evidence for treatment and prevention of uterine bleeding in patients with cancer, there is no specific guidance used universally for hematologic malignancies. This study evaluated prescribing patterns of agents used for treatment and prevention of uterine bleeding in patients receiving intensive chemotherapy for hematologic malignancies to provide guidance for a standardized approach for treatment and prevention of uterine bleeding within a single health system.
methodsEvaluation of prescribing patterns was performed via a dual-center, retrospective chart review of patients receiving intensive chemotherapy for hematologic malignancies and receiving preventative therapies, and/or treatment for uterine bleeding between January 1, 2018, and September 1, 2021. A guideline for the health system was drafted based on an assessment of results.
resultsA total of 91 patients were evaluated. For prevention of uterine bleeding, 68% of patients received leuprolide acetate alone. For treatment of uterine bleeding, 25% of patients required initiation of and/or increased doses of medroxyprogesterone. Fifty-seven percent of patients with uterine bleeding had adjustment of their baseline platelet transfusion goal from ≥ 10 K/cu mm to a goal of ≥ 20 K/cu mm or greater.
conclusionsBased on data from the retrospective chart review, an institutional guideline was created, including recommendations for patients to receive a 3-month formulation of leuprolide acetate with concomitant oral medroxyprogesterone at 20 mg/day for prevention of uterine bleeding. Further prospective studies are needed to determine optimal strategies for prevention and treatment of uterine bleeding in this patient population.
Indexed as
Identifiers
41489830What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.